March 18, 2019 / 6:17 AM / a month ago

BRIEF-Roche Presents Results Of Tecentriq Study

March 18 (Reuters) - Roche Holding AG:

* ROCHE TO PRESENT RESULTS OF THE LARGEST SAFETY STUDY OF ITS KIND WITH TECENTRIQ (ATEZOLIZUMAB) IN PATIENTS WITH METASTATIC BLADDER CANCER

* SAUL STUDY EVALUATED SAFETY OF TECENTRIQ IN APPROXIMATELY 1000 PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

* DATA FROM STUDY SHOWED THAT SAFETY AND EFFICACY WERE CONSISTENT WITH PREVIOUS STUDIES Source text for Eikon: Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below